The Heidelberg Engineering 2018 Xtreme Research Award has been presented to Dr. Osamah J. Saeedi, Associate Professor and Director of Clinical Research at the University of Maryland School of Medicine’s Department of Ophthalmology and Visual Sciences in Baltimore, Maryland, USA. The award recognises Dr. Saeedi’s in vivo imaging of ocular blood flow, which may enable detection of the earliest potential changes in conditions such as glaucoma, diabetic retinopathy and age related macular degeneration.
Dr. Saeedi presented a lecture entitled “Beyond Angiography: In Vivo Imaging of Ocular Erythrocytes” at the award ceremony, held during ARVO’s Annual Meeting in Hawaii.
Dr. Saeed’s ground breaking research is based on a novel technique that allows for labelling of individual erythrocytes (red blood cells) with the fluorescent dye Indocyanine Green (ICG). This technique, combined with dynamic confocal scanning laser imaging, offers the ability to visualise and potentially quantify ocular blood flow in a more granular fashion than ever before. While this research is still in early stages, the dynamics of individual erythrocytes may reveal undiscovered information about the physiological and biological processes at a cellular level within the eye.
“These new discoveries may shed new light on important aspects of ocular hemodynamics such as oxygenation and flow speed, allowing for improvement and/or validation of technologies such as OCT angiography,” said Ali Tafreshi, Director of Clinical Research at Heidelberg Engineering.
These new discoveries may shed new light on important aspects of ocular hemodynamics such as oxygenation and flow speed, allowing for improvement and/or validation of technologies such as OCT angiography
This technique, referred to as erythrocyte-mediated angiography (EMA), is based on the innovative approach of labelling individual red blood cells with the ICG fluorescent dye and then reinjecting them back into the body to enable acquisition of angiograms of the eye.
When combined with the video angiography functionality of the Spectralis HRA imaging platform, this novel labelling technique offers the ability to dynamically visualise and monitor the movement and pausing of individual red blood cells in vivo. Dr. Saeedi’s work intends to facilitate a better understanding of the biological processes associated with ocular hemodynamics in a way that incites the identification of new biomarkers for ocular diseases such as glaucoma, age related macular degeneration and diabetic retinopathy.
Although Dr. Saeedi’s main area of interest is glaucoma, his research1 is laying the groundwork for future studies that may reveal new and important diagnostic parameters for ocular and even systemic diseases.
Heidelberg explained that current ocular blood flow imaging techniques are limited in the amount of information they offer. “Conventional dye-based angiography imaging methods are able to visualise ocular blood flow dynamics only in the initial vessel filling phase. Dye-based angiography also mainly offers only two-dimensional visualisation of vasculature. While OCT angiography, provides non-invasive three-dimensional visualisation of vessel networks, it currently does not offer dynamic information relevant to disease diagnosis.
“Doppler OCT has been investigated for quantification of ocular blood flow, but this approach has yet to be proven as a reliable and feasible in vivo imaging technique.
“EMA, the novel technique established by Dr. Saeedi, may trigger the evolution of studies to evaluate ocular hemodynamics in a more refined fashion than existing methods, addressing some of the current key limitations in this area of research.”
Speaking of the EMA technique Dr. Saeedi said, “We have developed this novel technique to where it is now a safe and effective procedure in humans. With better understanding of microvasculature dynamics gained from EMA, we may see the earliest potential changes in conditions such as glaucoma, diabetic retinopathy and age related macular degeneration. This has the exciting potential to open the door to new treatments for these blinding diseases in the earliest stages, a goal we are actively working towards.”